The Prognostic Significance of Selected HLA Alleles on Prostate Cancer Outcome

Recently, we have shown that HLA-A*02:01 and HLA-A*24:02 in de novo metastatic prostate cancer (MPCa) an important role disease progression. Since MPCa represents a small group among patients diagnosed with (PCa), it was obvious to try extend the validity of our results larger cohorts PCa patients. Herein, analyzed irrespective their status at diagnosis include, besides MPCa, those localized (LPCa). Our goal specify prognostic value for overall survival (OS) prospectively early biochemical recurrence (BCR) castrate resistance (CR) as additional clinical endpoints prospective/retrospective manner, improve decisions covering all stages PCa. On univariate analysis, HLA-A alleles were significantly associated biomarkers BCR (p = 0.028; HR 1.822), OS 0.013; 1.547) showed trend CR 0.150; 1.239). multivariate proved be independent prognosticators 0.017; 2.008), 0.005; 1.615), 0.002; 2.063). Kaplan–Meier analyses revealed belonging HLA-A*02:01+HLA-A*24:02− progressed much faster had also shorter compared HLA-A*24:02+ Patients being HLA-A*02:01−HLA-A*24:02− exhibited varying outcomes, pointing presence potential value. data underline valuable may assist appropriate treatment follow-up schedule based on risk progression avoid over-diagnosis over-treatment.